Skip to Main Content

After years of emotional and legislative debate, the controversial “right-to-try” concept of expanding access to experimental medicines became law last month. But the authors of a new study suggest that the effort, which is designed to sideline the Food and Drug Administration, may have been unnecessary, because a previous regulatory program appeared to be working well.

How so?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!